Fig. 6: SETDB1 inhibition has anti-tumoral effect in vivo.
A Schematic of in vivo experiment where NSG mice were injected subcutaneously with OMM1 cells. When the tumor reached 100 mm3, mice began a treatment regimen of vehicle (PBS) or Mithramycin A via intraperitoneal injection (1 mg/kg) three times per week. B Plot showing tumor volume for individual mice bearing a OMM1 cell xenograft treated with PBS (Control mice in red) or with Mithramycin A (Mithramycin A-treated mice in blue). C Kaplan–Meier analyses of tumor growth to ethical endpoint for mice bearing the OMM1 cell xenografts showing time to 0.8 cm3 in vehicle (red) or 1 mg/kg Mithramycin A (blue) treated mice. Log-rank (Mantel–Cox) test was performed for comparison between groups. ***p = 0.0005.
